A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation

BACKGROUND: Presently, few options are available for refractory colorectal cancer (CRC). O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation is a frequent and early event in CRC tumourigenesis. This epigenetic silencing is a predictor of response to the alkylating drug temozolomide i...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Cancer
Päätekijät: Calegari, M A, Inno, A, Monterisi, S, Orlandi, A, Santini, D, Basso, M, Cassano, A, Martini, M, Cenci, T, de Pascalis, I, Camarda, F, Barbaro, B, Larocca, L M, Gori, S, Tonini, G, Barone, C
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2017
Aiheet:
Clinical Study
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5482728/
https://ncbi.nlm.nih.gov/pubmed/28427088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.109
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia